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Abstract
Introduction: C-X-C motif chemokine 10 (CXCL10) is produced in response to interferon-γ, and tumor necrosis factor-α
(TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary lymphoid
tissues, and the expression is upregulated by TNF-α, via T cell stimulation. It appears that CXCL10 and CXCL13 could play
a potential role in the pathogenesis of adult-onset Still’s disease (AOSD), therefore, we investigated the associations
between CXCL10 and CXCL13 levels and clinical manifestations in patients with active AOSD.
Methods: Blood samples were collected from 39 active AOSD patients, 32 rheumatoid arthritis (RA) patients and 40
healthy controls (HC). Of the AOSD patients, follow-up samples were collected from 15 9.6 ± 9.2 months later. Serum
levels of CXCL10 and CXCL13 were determined using enzyme-linked immunosorbent assay. CXCL10, CXCL13, and
C-X-C chemokine receptor type 3 (CXCR3) expression levels in biopsy specimens obtained from 26 AOSD patients
with skin rashes were investigated via immunohistochemistry.
Results: The CXCL10 levels in AOSD patients (1,031.3 ± 2,019.6 pg/mL) were higher than in RA (146.3 ± 91.4 pg/mL,
p = 0.008) and HC (104.4 ± 47.9 pg/mL, p = 0.006). Also, the CXCL13 levels of AOSD patients (158.8 ± 151.2 pg/mL) were
higher than those of RA (54.4 ± 61.1 pg/mL, p < 0.001) and HC (23.5 ± 18.1 pg/mL, p < 0.001). Serum CXCL10 levels
correlated with ferritin and systemic scores. Serum CXCL13 levels correlated with those of hemoglobin, C-reactive protein,
ferritin, and albumin, and systemic scores. In follow-up AOSD patients, the levels of CXCL10 and CXCL13 fell significantly
(153.7 ± 130.1 pg/mL, p = 0.002, and 89.1 ± 117.4 pg/mL, p = 0.001, respectively). On immunohistochemistry, the
percentages of inflammatory cells expressing CXCL10 ranged from 1 to 85 %, CXCL13 from 1 to 72 %, and CXCR3 from 2
to 65 %. The percentage of CXCL10-positive inflammatory cells was higher in skin biopsy samples exhibiting mucin
deposition than in those that did not (p = 0.01). CXCL13 levels were correlated with those of CD4 and CD68.
Conclusions: Serum CXCL10 and CXCL13 levels may serve as clinical markers for assessment of disease activity in
AOSD. CXCL10/CXCR3 and CXCL13 may contribute to the inflammatory response, especially skin manifestations
thereof, in AOSD.
Introduction
Adult-onset Still’s disease (AOSD) is a systemic inflamma-
tory disease exhibiting various clinical manifestations char-
acterized by a high spiking fever, an evanescent skin rash,
polyarthralgia, and hepatosplenomegaly [1, 2]. Acute-phase
reactants, such as the C-reactive protein (CRP) and ferritin
levels, erythrocyte sedimentation rate (ESR), and leukocyte
and platelet counts, are typically elevated. Although initial
manifestations (the systemic symptoms) are similar in all
patients, the clinical courses differ; several patterns are evi-
dent. These include systemic monocyclic, intermittent or
polycyclic, and chronic articular, patterns [2–4]. Although
the pathogenesis of AOSD remains unknown, several
factors including infections, genetic factors, and immune
dysregulation have been suggested to contribute to devel-
opment of the disease [5, 6]. Several studies with small
case numbers have reported associations between distinct
human leukocyte antigens alleles and AOSD, but the data
* Correspondence: nakhada@naver.com
2Department of Rheumatology, Ajou University School of Medicine, 164
Worldcup-ro, Yeongtong-gu, Suwon 443-380, South Korea
Full list of author information is available at the end of the article
© 2015 Han et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Han et al. Arthritis Research & Therapy  (2015) 17:260 
DOI 10.1186/s13075-015-0773-4
are often conflicting, varying with ethnicity and/or disease
pattern [7]. Several cytokines including interleukin-1 (IL-1),
tumor necrosis factor-α (TNF-α), IL-18, IL-8, and IL-6 have
been suggested to play roles in the pathogenesis of AOSD
[8, 9].
As is true of other cytokines, the levels of several
chemokines have been reported to change under various
systemic conditions, and such changes may serve as
useful diagnostic and prognostic markers [10]. It ap-
pears that proinflammatory chemokines may play roles
in AOSD pathogenesis characterized by various sys-
temic symptoms, but studies on such chemokines are
limited in number. Chemokines are relatively small-
sized (8–14 kDa) chemotactic cytokines produced by a
variety of cells, and are characterized by the presence
of three to four conserved cysteine residues [10, 11].
Proinflammatory chemokines are produced by cells pri-
marily to recruit leukocytes to the sites of inflammation
or infection. IL-8, or C-X-C motif chemokine 8
(CXCL8), mobilizes, activates, and degranulates neutro-
phils at sites of inflammation. The IL-8 levels have been
found to be elevated in AOSD patients, and may serve
as a biomarker predicting the persistence of arthritis [8,
9]. A recent study showed that the levels of C-X3-C
motif ligand 1, CXCL8, CXCL10, CC-chemokine ligand
2 (CCL2), and CCL3 in the sera of 19 AOSD patients
were higher than those of healthy controls (HC) [12].
CXCL10 is produced in response to interferon-γ (IFN-γ),
and TNF-α triggers the accumulation of activated lympho-
cytes via interaction with a specific receptor, C-X-C chemo-
kine receptor type 3 (CXCR3), creating an amplification
feedback loop [13, 14]. CXCL10 is secreted by several cell
types, including T cells, monocytes, neutrophils, and
endothelial cells. CXCL13 is constitutively expressed by
follicular dendritic cells in secondary lymphoid tissues,
and is required for lymphoid follicle formation. The ex-
pression thereof is upregulated by TNF-α, via T cell stimu-
lation, and CXCR3 and CXCR5 are known to serve as
receptors for CXCL13 [11, 15]. CXCL13 is also associated
with formation of extranodal lymphoid aggregates, and
attracts B cells to secondary lymphoid tissue, facilitating
local inflammation and antibody generation [15, 16].
Therefore, CXCL13 is thought to be a pivotal chemokine
in establishment of the adaptive immune response. These
chemokines and their receptors seem to be involved in
several inflammatory diseases, including rheumatoid arth-
ritis (RA), systemic lupus erythematosus (SLE), and in-
flammatory bowel disease [14, 17–24]. Furthermore, a
recent study showed that injury-induced S100A8/A9 stim-
ulated CXCL10 production in monocytes and macro-
phages [25]. Previously, we showed that S100A8/A9 levels
were elevated in AOSD patients compared to HC, and
S100A8/A9 levels correlated with those of AOSD disease
activity markers [26]. Therefore, the aim of the present
study was to determine the serum levels of CXCL10 and
CXCL13, and to investigate their associations with clinical
activities, in patients with active AOSD. To explore the in
vivo involvement of these chemokines in AOSD, we per-
formed immunohistochemical analysis of skin biopsy for
CXCL10, CXCL13, and their receptor, CXCR3 in 26 pa-
tients with active untreated AOSD.
Materials and methods
Subjects
Thirty-nine active AOSD patients, 32 RA patients and 40
HC were included in the present study, and serum sam-
ples were collected from all subjects. AOSD patients were
diagnosed using Yamaguchi’s criteria after exclusion of
those who had infectious, neoplastic and autoimmune dis-
orders [27]. Twenty-one patients of AOSD were evaluated
with tuberculosis skin test or Mycobacterium tuberculosis-
specific T cell IFN-γ assays before starting high-dose glu-
cocorticosteroid therapy, and only two patients had latent
tuberculosis. The HC was recruited using a screening
questionnaire from healthy individuals without history of
exposure to Mycobacterium tuberculosis and medical
history of autoimmune, rheumatic, and any other diseases
through the public announcement. Of the 39 AOSD
patients, follow-up samples were collected from 15 9.6 ±
9.2 months later. All blood samples were stored at −70 °C
immediately after collection. Information on medical
histories, clinical symptoms, and the findings of physical
examinations was entered into a database together with
serum test results. Each patient underwent a series of
laboratory tests, including a complete blood count; ESR
evaluation; assessment of CRP, rheumatoid factor (RF),
anti-nuclear antibody (ANA), and ferritin levels (normal
13–150 ng/mL for females and 30–400 ng/mL for males);
liver function testing; and urinalysis. AOSD disease activ-
ity was scored as previously described; scores ranged from
0 to 12 with 1 point being given for each of the fol-
lowing manifestations: fever, a typical rash, pleuritis,
pneumonia, pericarditis, hepatomegaly or abnormal
liver function test data, splenomegaly, lymphadenop-
athy, leukocytosis ≥ 15,000/mm2, sore throat, myalgia,
and abdominal pain [28]. This study was approved by
Ajou University Hospital Institutional Review Board
(IRB No. BMR-KSP-14-406), and informed consent
was obtained from all subjects.
CXCL10 and CXCL13 assays
CXCL10 levels were measured using commercial enzyme-
linked immunosorbent assay (ELISA) kits (R & D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. CXCL13 levels were also determined using an
ELISA kit (R & D Systems) according to the manufacturer’s
instructions.
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Histopathological analysis of skin biopsy sample
Skin biopsies were obtained from 26 patients with AOSD,
and we examined hematoxylin and eosin-stained sections.
All slides were independently examined by three patholo-
gists (JHH, JEK, and HY) with respect to the following skin
histological parameters: (1) epidermal change; (2) extent of
inflammatory cell infiltration; and the presence of (3) kar-
yorrhexis, (4) vasculitis, and (5) interstitial mucin.
Immunohistochemical evaluation
Immunohistochemistry were performed on the formalin-
fixed paraffin-embedded sections using a Benchmark XT
automated staining system (Ventana Medical Systems Inc.,
Tucson, AZ, USA). The primary antibodies used were:
CD4, 1:10 and CD8, 1:50 (Thermo Fisher Scientific,
Fremont, CA, USA); CD68, 1:200 (Novocastra Laboratories
Ltd, Newcastle, UK); CXCL10, 1:50; CXCL13, 1:50; and
CXCR3, 1:20 (R & D Systems). Detection was achieved
using a Ventana Optiview DAB kit (Ventana Medical
Systems). Scores were calculated by dividing the numbers
of positive inflammatory cells by the numbers of all inflam-
matory cells, expressed as percentages (CXCL10, CXCL13,
and CXCR3) or graded on a scale from 1 to 3: 1:1–33 %; 2,
34–66 %; and 3, 67–100 % (CD4, CD8, and CD68).
Statistical analyses
All data are shown as means ± standard deviations. Differ-
ences among CXCL10 and CXCL13 levels were evaluated
using the independent t test or the Mann–Whitney U test.
Correlations between histological scores and disease activ-
ity marker levels were evaluated using Pearson’s correl-
ation test or Spearman’s correlation test. The Wilcoxon
signed-rank test was also used to compare CXCL10 and
CXCL13 levels in patients who underwent follow-up
serum sampling. All statistical analyses were performed
using SPSS version 20.0 (IBM Corp., Armonk, NY, USA).
A p value <0.05 was regarded as indicative of statistical
significance.
Results
Clinical characteristics of the patients
Table 1 summarizes the clinical characteristics of the 39
patients with AOSD, RA and the HC. The mean age of
AOSD patients was 42.2 ± 15.8 years and females com-
prised 92.3 % of all patients. There was no significant
difference in age or gender between the groups except age
between RA and HC (p = 0.001). The principal clinical
symptoms of AOSD patients included a high spiking fever
(87.2 %), a skin rash (82.1 %), arthritis (61.5 %), sore throat
(53.8 %), and splenomegaly (25.6 %). In RF-positive
patients, a diagnosis of RA was excluded using the 1987
American College of Rheumatology (ACR) criteria [29]. In
ANA-positive patients, a diagnosis of SLE was excluded
using the 1982 ACR criteria [30]. Of the 39 AOSD
patients, 30 were in the initial stages of high-level disease
activity before commencement of treatment. The other
nine were in flare during follow-up of AOSD, and their
disease duration was 28.2 ± 23.2 months. Among the nine
patients, three patients were discontinued with their medi-
cations before the flare. Five patients were treated with
methotrexate, and one patient was treated with azathio-
prine at the time of sampling. Daily glucocorticosteroid
dose of the six AOSD patients was 5.3 ± 6.3 mg prednisol-
one equivalent. Nineteen patients had AOSD of the
monophasic pattern, six disease of the polycyclic pattern,
and five disease of the chronic articular pattern, among
30 patients exhibiting high-level disease activity prior to
commencement of treatment (thus at the time of
sampling). Disease duration of the RA patients was
41.2 ± 26.3 months. In RA patients, 21 patients
Table 1 Clinical characteristics of patients
AOSD (n = 39) RA (n = 32) HC (n = 40)
Age (years) 42.2 ± 15.8 44.7 ± 8 37.7± 8.7
Gender (F/M) 36/3 27/5 35/5
Fever 34 (87.2)
Sore throat 21 (53.8)





Arthritis 24 (61.5) 31 (96.9)
Hemoglobin, g/dL 11 ± 1.8 12.8 ± 1.4
Leukocytes, /μL 13,130 ± 5,015 7,613 ± 3,061
Platelets, x103/μL 316.2 ± 117.9 267.9 ± 78.9
Ferritin, ng/mL 7,229.7 ± 13,091.1
ESR, mm/h 64.6 ± 29.3 31.9 ± 24.7
CRP, mg/dL 8.53 ± 6.68 1.07 ± 2.41




Bilirubin, mg/dL 0.67 ± 0.8 0.58 ± 0.2
Albumin, g/dL 3.74 ± 0.64 4.48 ± 0.32
ANA positivity 6 (15.4) 9 (28.1)
RF positivity 4 (10.3) 29 (90.6)
Systemic score 4.79 ± 1.81
DAS-28 3.91 ± 1.2
AOSD adult onset Still’s disease, RA rheumatoid arthritis, HC healthy controls,
ESR erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate
transaminase, ALT alanine transaminase, ANA antinuclear antibody, RF
rheumatoid factor. DAS-28, disease activity score including 28 joints. All values
are presented as numbers (with percentages) or means ± standard deviations.
The systemic scoring system of Pouchot et al. [28] assigns a score from 0 to 12
with 1 point for each of the following manifestations: fever, typical rash,
pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function
test data, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/mm2, sore
throat, myalgia, and abdominal pain
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(65.6 %) were treated with methotrexate at the time
of sampling, four (12.5 %) with sulfasalazine, six
(18.8 %) with leflunomide, and one patient with adali-
mumab (3.1 %), respectively. Daily glucocorticosteroid
dose of the RA patients was 2.23 ± 2.
Of the AOSD patients, five (12.8 %) were diagnosed
with reactive hemophagocytic syndrome (RHS). These pa-
tients were diagnosed to RHS by tissue biopsy or clinical
features [31].
Serum CXCL10 and CXCL13 levels
Figure 1 shows the CXCL10 and CXCL13 levels in AOSD
patients, RA patients and HC. The CXCL10 levels in
AOSD patients (1,031.3 ± 2,019.6 pg/mL) were higher
than in RA (146.3 ± 91.4 pg/mL, p = 0.008) and HC (104.4
± 47.9 pg/mL, p = 0.006) (Fig. 1a). Also, the CXCL13 levels
of AOSD patients (158.8 ± 151.2 pg/mL) were higher
than those of RA (54.4 ± 61.1 pg/mL, p < 0.001) and HC
(23.5 ± 18.1 pg/mL, p < 0.001) (Fig. 1b). We compared the
CXCL10 and CXCL13 levels between patients with initially
active AOSD and those experiencing flares during follow-
up. The CXCL10 levels of the 30 initially active AOSD
patients (1,309.5 ± 2,272.1 pg/mL) were higher than those
of the nine flare patients (204.3 ± 90 pg/mL, p < 0.001).
However, the CXCL13 levels did not differ between the
two groups (163 ± 147.6 pg/mL vs. 157 ± 175.4 pg/mL,
p = 0.635).
Comparing the CXCL10 and CXCL13 levels ac-
cording to existence of RHS, we found that serum
CXCL13 were significantly higher in AOSD patients
with RHS (229.6 ± 90.3 pg/mL) than in patients with-
out RHS (151.6 ± 157.6 pg/mL, p = 0.039), but serum
CXCL10 did not differ between the two groups.
When we compared CXCL10 and CXCL13 levels by
AOSD clinical course (monocyclic vs. polycyclic vs.
chronic articular) of 30 patients with high-level dis-
ease activity, those levels did not differ among the
three groups (data not shown).
Correlation between serum CXCL10 or CXCL13 levels and
disease activity in AOSD patients
The correlations between the levels of pre-existent disease
activity markers and those of serum CXCL10 or CXCL13
in AOSD patients are shown in Table 2. Serum CXCL10
levels correlated with ferritin levels (r= 0.444, p = 0.005),
Fig. 1 The levels of CXCL10 (a) and CXCL13 (b) in 39 adult-onset
Still’s disease (AOSD) patients, 32 rheumatoid arthritis (RA) patients
and 40 healthy controls (HC). Data are expressed as means ± SDs.
The independent t test was used to perform statistical analysis.
CXCL10, C-X-C motif chemokine 10, CXCL13, C-X-C motif
chemokine 13
Table 2 Correlations between C-X-C motif chemokine 10
(CXCL10) and CXCL13 levels and those of disease activity
markers in 39 adult-onset Still’s disease patients
Disease
activity marker
Correlation coefficient, r (p-value)
CXCL10 CXCL13 Systemic score
Systemic score 0.421 (0.008) 0.809 (<0.001)
Leukocytes 0.052 (0.753) 0.21 (0.2) 0.362 (0.024)
Hemoglobin −0.137 (0.406) −0.464 (0.003) −0.3 (0.063)
Platelets −0.021 (0.899) 0.09 (0.587) 0.042 (0.8)
ESR −0.132 (0.423) 0.11 (0.504) 0.191 (0.244)
CRP 0.147 (0.373) 0.534 (<0.001) 0.619 (<0.001)
Ferritin 0.444 (0.005) 0.405 (0.011) 0.5 (0.001)
Albumin −0.216 (0.187) −0.398 (0.012) −0.475 (0.002)
Bilirubin −0.116 (0.482) −0.369 (0.021) −0.392 (0.013)
AST 0.412 (0.009) 0.162 (0.325) 0.301 (0.062)
ALT 0.3 (0.064) 0.06 (0.715) 0.209 (0.202)
CXCL10 0.428 (0.007) 0.421 (0.008)
CXCL13 0.428 (0.007) 0.809 (<0.001)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate
transaminase, ALT alanine transaminase. Spearman’s correlation coefficients
were calculated. The systemic scoring system of Pouchot et al. [28] assigns a
score from 0 to 12 with 1 point for each of the following manifestations: fever,
typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver
function test data, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/mm2,
sore throat, myalgia, and abdominal pain
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aspartate transaminase (AST) levels (r = 0.412, p = 0.009),
and systemic scores (r = 0.421, p = 0.008). Serum CXCL13
levels correlated with hemoglobin levels (r = −0.464, p =
0.003), CRP levels (r = 0.534, p < 0.001), ferritin levels (r =
0.405, p = 0.011), albumin levels (r = −0.398, p = 0.012),
and the systemic scores (r = 0.809, p < 0.001). Also,
serum CXCL10 levels correlated with those of
CXCL13 (r = 0.428, p = 0.007).
Furthermore, we compared the correlation coefficient
between systemic scores and several inflammatory markers
including CXCL10 and CXCL13. Systemic scores have the
best correlation coefficient with CXCL13 levels (r = 0.809)
than CRP (r = 0.619, p < 0.001), ferritin (r = 0.5, p = 0.001),
CXCL10 (r= 0.0421, p = 0.008), and ESR (r = 0.191, p =
0.244).
Changes in serum CXCL10 and CXCL13 levels in follow-up
AOSD patients
Repeat serum samples were collected from 15 AOSD
patients at 9.6 ± 9.2 months after the first samplings. The
CXCL10 level was 153.7 ± 130.1 pg/mL, and that of
CXCL13 89.1 ± 117.4 pg/mL. The systemic scores were
1.13 ± 1.19. In AOSD patients who were followed up,
systemic scores decreased somewhat and serum CXCL10
and CXCL13 levels significantly decreased (p = 0.002 and
p = 0.001) (Fig. 2). We calculated correlations between
changes in CXCL10 or CXCL13 levels and changes in
disease activity marker levels (Table 3). The change in
CXCL10 was positively correlated only with the change
in systemic score (r = 0.516, p = 0.049). The change in
CXCL13 was positively correlated with both the change in
Fig. 2 The levels of CXCL10 (a) and CXCL13 (b) in 15 follow-up adult-onset Still’s disease (AOSD) patients. Data are expressed as means ± SDs.
The Wilcoxon signed-rank test was used to perform statistical analysis. CXCL10, C-X-C motif chemokine 10, CXCL13 C-X-C motif chemokine 13
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CRP level (r = 0.604, p = 0.017) and the change in systemic
score (r = 0.642, p = 0.01).
Histopathological characteristics of skin
The skin manifestations of 17 patients were maculopapular
eruptions on the upper and lower extremities, and the
trunk (n = 17, 65.4 %). Five patients (19.2 %) had persistent
pruritic eruptions, and two patients had papulopustular
lesions on the trunk. Two patients had painful swelling of
the low extremities. Most skin biopsies exhibited mild
lymphocytic or histiocytic infiltration in the upper dermis.
Nuclear debris was frequently evident in the dermis (14
cases; 53.8 %). Neutrophil infiltrations were shown in some
cases (seven cases; 26.9 %), More than half of all cases
showed interstitial mucin deposition. Some cases exhibited
interface dermatitis with keratinocyte necrosis or basal
vacuolization.
Immunohistochemical data
The percentage of cells positive for CD8 was higher than
that for CD68 (57.7 %). The number of CD8-positive lym-
phocytes was higher than that of CD4-positive lympho-
cytes in almost all cases (88.5 %). To control for CXCL10,
CXCL13, and CXCR3 immunohistochemical evaluations,
lymphoid cells in the paracortical zone or germinal center
of a reactive lymph node were stained. The antibodies
revealed a granular pattern of cytoplasmic staining. The
staining patterns of inflammatory cells in skin biopsies
were similar to those of lymphoid cells in a lymph node
(Fig. 3). The percentages of inflammatory cells expressing
CXCL10 ranged from 1 to 85 % (mean, 25.8 ± 23.3 %),
CXCL13 from 1 to 72 % (mean, 23.3 ± 22.2 %), and
CXCR3 from 2 to 65 % (mean, 16.4 ± 18.5 %). The
percentages of inflammatory cells expressing CXCL10 and
CXCL13 were not correlated with systemic score, ESR,
CRP and ferritin. CXCL10-, CXCL13-, and CXCR3-
positive inflammatory cells did not differ in terms of
the presence of neutrophil infiltrations, keratinocyte
vacuolization or karyorrhexis (Additional file 1). How-
ever, the percentage of CXCL10-positive inflammatory
cells was higher in patients exhibiting mucin depos-
ition than in those who did not (p = 0.01).
The correlations between CD4, CD8, and CD68
grades, and the percentages of CXCL10-, CXCR3-,
and CXCL13-positive inflammatory cells in the skin
of AOSD patients, are shown in Additional file 2.
CXCL10 and CXCR3 levels did not correlate with any
grade. However, CXCL13 levels were correlated with
those of CD4 (r = 0.453, p = 0.02) and CD68 (r = 0.464,
p = 0.017).
Discussion
To evaluate the clinical utilities of serum CXCL10 and
CXCL13 levels, we studied these markers of AOSD pa-
tients and compared the levels with those of RA and
HC. Moreover, we also confirmed that these markers
and their receptor, CXCR3, immunohistochemically
stained in skin rash material from AOSD patients. This
is the first study to show that serum CXCL13 levels are
significantly higher in patients with active AOSD than in
RA and HC. Furthermore, the serum levels of CXCL10
and CXCL13 in patients with AOSD correlated with
those of several inflammatory markers, and systemic
scores, and the serum levels of CXCL10 and CXCL13
fell upon reduction in disease activity in follow-up
AOSD patients.
CXCL10 has been detected in the serum, synovial fluid,
and synovial tissues of RA patients, and CXCR3, the re-
ceptor thereof, is expressed in T cell-rich areas of inflamed
synovial tissue [20, 21, 24, 32, 33]. The elevated levels of
CXCR3 in synovial fluid T cells have been associated with
high levels of IFN-γ, suggesting that a Th1 phenotype is
preferentially in play [32]. Only one study has reported
elevated serum CXCL10 levels in 19 patients with AOSD
compared to HC [12]. However, CXCL10 levels were not
shown to be correlated with those of ferritin, CRP, or IL-
18. In our present study, the serum CXCL10 levels of 39
AOSD patients were significantly higher than those of RA
and HC, and serum CXCL10 levels were significantly cor-
related with the levels of known disease activity markers,
including ferritin and AST, and the systemic score. Most
follow-up AOSD patients exhibited significantly reduced
CXCL10 levels after improvement in disease, although
changes in CXCL10 levels were correlated only with
Table 3 Correlations between changes in serum C-X-C motif
chemokine 10 (CXCL10) or CXCL13 levels and those of disease
activity markers in follow-up adult-onset Still’s disease patients
Disease activity
marker
Correlation coefficient, r (p-value)
Delta CXCL10 Delta CXCL13
Delta systemic score 0.516 (0.049) 0.642 (0.01)
Delta leukocytes 0.036 (0.899) 0.356(0.193)
Delta hemoglobin −0.175 (0.532) 0.177 (0.528)
Delta platelets 0.289 (0.296) 0.036 (0.899)
Delta ESR 0.029 (0.919) 0.175 (0.533)
Delta CRP 0.05 (0.86) 0.604 (0.017)
Delta ferritin 0.35 (0.201) 0.425 (0.114)
Delta albumin −0.136 (0.628) 0.142 (0.614)
Delta bilirubin 0.061 (0.829) −0.106 (0.707)
Delta AST 0.438 (0.103) −0.116 (0.68)
Delta ALT 0.464 (0.081) −0.468 (0.079)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate
transaminase, ALT alanine transaminase. Spearman’s correlation coefficients
were calculated. The systemic scoring system of Pouchot et al. [28] assigns a
score from 0 to 12 with 1 point for each of the following manifestations: fever,
typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver
function test data, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/
mm2, sore throat, myalgia, and abdominal pain
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changes in systemic scores. Furthermore, CXCL10 and
the receptor thereof, CXCR3, were expressed in the
affected skin of AOSD patients, and enhanced CXCL10
staining was evident in inflammatory cells of skin lesions
with mucin depositions. Actually, in lupus erythematosus
tumidus, a lupus erythematosus subset characterized by
dense perivascular lymphocytic infiltration and mucin de-
posits, CXCL10 were mainly expressed in the perivascular
folds, again reflecting the typical inflammatory pattern
[34]. Therefore, such results suggest that CXCL10 plays a
role in the skin dermal injury of AOSD, and serum levels
may be a good marker for monitoring of disease activity.
Large amounts of type 1 inflammatory cytokines, includ-
ing IFN-γ, TNF-α, and IL-18, are present in the serum and
diseased tissues (including the liver and skin) of AOSD
patients [9, 26, 35–37]. These cytokines may sustain sys-
temic and local proinflammatory responses and upregulate
CXCL10 expression. In turn, CXCL10 may participate in
maintenance of the default Th1 polarization noted during
AOSD inflammation, because CXCL10 is known to upreg-
ulate cytokine synthesis in human Th1 cells [33, 37].
Proinflammatory cytokines, such as TNF-α and IL-6,
play roles upstream of CXCL13 expression and lymphoid
tissue organization, as demonstrated in animal models of
lymphoid tissue generation [38, 39]. Many researchers have
measured CXCL13 levels in the sera and synovial tissues of
RA patients or mouse models of RA [15, 16, 21–23, 40].
One recent study showed that synovial CXCL13 could
serve as a marker of more severe RA [23]. Greison et al.
[22] proposed that high CXCL13 concentrations indicated
recent-onset inflammation that might respond better to
early aggressive treatment. Although acute AOSD patients
have similar symptoms, including fever, rash, and myalgia,
only some exhibit the chronic articular pattern associated
with tissue destruction [3, 36]. Therefore, we hypothesized
that CXCL13 might play a key role in triggering the appear-
ance of the chronic articular pattern after systemic disease
manifestations, and measured CXCL13 levels in the serum
and skin of active AOSD patients. Serum CXCL13 levels in
AOSD patients were significantly higher than those of RA
and HC, and serum CXCL13 levels strongly correlated with
the levels of several disease activity markers, including
those of hemoglobin, albumin, AST, CRP, and ferritin; and
the systemic score. Furthermore, when we compared the
correlation coefficient between systemic scores and several
inflammatory markers including CXCL10 and CXCL13,
systemic score have the best correlation with CXCL13
levels than CRP, ferritin, CXCL10, and ESR. Most follow-up
AOSD patients exhibited significantly decreased CXCL13
levels after improvement in disease activity, and changes in
Fig. 3 CXCL10 (a, b), CXCL13 (c, d), and CXCR3 (e, f) expression in inflammatory cells in skin biopsy material of patients with adult-onset Still’s
disease (original magnification, ×400). Representative instances of rare expression (a, c, e) and frequent expression (b, d, f) are shown. CXCL10,
C-X-C motif chemokine 10, CXCL13 C-X-C motif chemokine 13, CXCR3 C-X-C chemokine receptor type 3
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serum CXCL13 levels were always correlated with changes
in CRP levels and systemic scores, although the number of
follow-up patients was small. Furthermore, we found that
serum CXCL13 levels were significantly higher in AOSD
patients with RHS than in patients without RHS, and that
systemic scores have the best correlation coefficient with
CXCL13 levels. These results strongly suggest that CXCL13
plays a significant role in the pathogenesis, clinical mani-
festation and severity such as RHS in AOSD, and can serve
as a useful marker for monitoring disease activity. CXCL13
was also expressed in skin affected by AOSD; variable per-
centages of inflammatory cells were positive for this
material. Such staining was correlated with the numbers
of CD4- and CD68-stained inflammatory cells. Although
the percentage of the inflammatory cells were CD8+ T
cells were higher than that of macrophages and CD4+ T
cells, we can suggest that CXCL13 is expressed or secreted
by macrophages or CD4+ T cells in the patients with
AOSD. CXCL13-producing CD4+ T cells may be a CD4
subset other than Th1, Th2, TH17 or CXCR5+ follicular
helper T cells as in chronic inflammatory disorders such
as RA [14]. Gene expression profiling has identified genes
uniquely expressed by human germinal-center T helper
cells [41]. However, we did not find any difference in
CXCL13 levels among patients with different AOSD dis-
ease patterns. Although a few reports on differences in
patient genetic backgrounds, cytokine levels, or clinical
features of chronic articular AOSD compared with non-
chronic articular or monophasic AOSD, have appeared,
studies on the pathogenesis of the various AOSD patterns
are few in number [8, 36, 42]. In the present work, the
CXCL13 levels did not differ among patients exhibiting
different disease courses, but the number of AOSD
patients with the chronic articular pattern of disease was
small. Also, elevated CXCL13 levels could differentially
affect the synovial recruitment of inflammatory cells in
AOSD patients of different genetic backgrounds. Thus,
further work with larger sample sizes, and a genetic study,
is required to evaluate the effect of CXCL13 on progres-
sion to the chronic articular pattern in AOSD patients.
The limitations of this study include the lack of a normal
skin and follow-up skin biopsy in AOSD for comparison
with chemokine expression. We did not compare these
markers with other febrile disorders for diagnostic value of
these markers, and had a relatively small sample size for
subgroup analysis and comparison with follow-up samples.
Further studies involving larger sample size are required for
evaluating usefulness of these markers in AOSD patients
with control groups of other febrile disorders such as
sepsis.
Conclusions
We found significantly higher levels of CXCL10 and
CXCL13 in the serum from patients with active AOSD. We
also found that most follow-up AOSD patients exhibited
reduced CXCL10 and CXCL13 levels after improvement in
disease activity. These results indicate that CXCL10 and
CXCL13 may play important roles in the pathogenesis of
the acute inflammatory process in AOSD, although the
levels did not significantly differ among the various AOSD
disease courses. This exploration of chemokine levels in
AOSD not only improves our understanding of the role
played by such materials in immunopathogenesis but also
lays the foundation for development of novel therapeutic
strategies, such as anti-CXCL10 antibody administration,
for AOSD.
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